Coloplast A/S Interim Financial Highlights for 2024/25
Coloplast A/S has recently announced its interim financial results for the period from 1 October 2024 to 30 June 2025. This report unveils the company's impressive organic growth and highlights its strategies for maintaining its market position.
Remarkable Growth Figures
The latest results showcase an organic growth rate of 7% in Q3, alongside an EBIT margin of 28%. Although reported revenue in DKK experienced a slight growth of 1%, this was primarily influenced by currency fluctuations and the recent divestment in their Skin Care division.
Business Area Performance
Various segments within Coloplast A/S demonstrated distinct growth trajectories:
- Ostomy Care achieved 6% growth, experiencing widespread contributions globally, with only China falling behind expectations.
- Continence Care outperformed with an 8% growth, underpinned by the strong performance of the Luja™ product line.
- Voice and Respiratory Care rose by 9% due to sustained demand in both laryngectomy and tracheostomy products.
- Advanced Wound Care saw a slight decline of 2%, mainly due to an anticipated drop in revenue from a product return affecting the Chinese market.
- Interventional Urology's growth was modest at 1%, thanks to a strong showing in the US Men's Health sector, despite setbacks from product recalls.
Financial Metrics Overview
The overall financial picture for the first nine months of the 2024/25 fiscal year reveals:
- An organic growth of 7% across sectors and a reported EBIT of DKK 5,718 million, reflecting a robust 4% increase year-on-year.
- The EBIT margin remained stable at 27% compared to the previous year.
- Adjusted net profit before special items showed a slight decline to DKK 3,778 million, impacted by net financial expenses.
- Despite fluctuations, the adjusted ROIC after tax held steady at 15%.
Future Growth Prospects
Looking ahead, Coloplast maintains its guidance for FY 2024/25, anticipating continued organic growth around 7% with an EBIT margin between 27% and 28%. This optimism is supported by promising trends in various business areas, although challenges from the Advanced Wound Dressings product returns are acknowledged.
CEO Insights on Company Strategy
Lars Rasmussen, interim CEO of Coloplast, commented on the third-quarter results, stating: “We have delivered as expected, identifying strong growth in key areas while addressing challenges in certain markets. Our strategic initiatives are designed to enhance our global footprint, and we are excited to share our 2030 strategy during our upcoming Capital Markets Day.”
Upcoming Conference Call
Coloplast will host a conference call on 19 August 2025 at 11:00 CEST. This session will dive deeper into the Q3 performance and outline future directions. Those wishing to participate can register in advance to receive dial-in information.
For further inquiries, please reach out to:
Investors and Analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111
Aleksandra Dimovska
Vice President, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Email: dka_dim@coloplast.com
Kristine Husted Munk
Senior Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 3266
Email: dk_khu@coloplast.com
Simone Dyrby Helvind
Senior Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 2981
Email: dk_sdk@coloplast.com
Press and Media
Peter Mønster
Sr. Media Relations Manager
Tel. +45 4911 2623
Email: dk_pete@coloplast.com
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Company reg. (CVR) no. 69749917
Frequently Asked Questions
What were Coloplast A/S's organic growth rates for Q3 2024/25?
For Q3, Coloplast A/S achieved an organic growth rate of 7% across its business segments.
What is the EBIT margin reported for Q3 2024/25?
The EBIT margin reported for Q3 was 28%, showing solid performance against the previous year's figures.
What are the growth rates for individual business areas in 2024/25?
Business areas reported growth rates as follows: Ostomy Care (6%), Continence Care (8%), Voice and Respiratory Care (9%), Advanced Wound Care (4%), and Interventional Urology (4%).
How did the recent divestment impact revenue?
The divestment from Skin Care negatively influenced reported revenue, though precise figures were not disclosed.
How can investors get in touch with Coloplast A/S?
Investors can reach out to the Investor Relations team via the provided contact information or register for the upcoming conference call.
